首页> 外国专利> Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis

Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis

机译:噻唑烷和恶唑烷衍生物用于治疗急性心肌梗塞和抑制心肌细胞凋亡

摘要

It has been demonstrated that antidiabetic thiazolidine and oxazolidine derivatives (glitazones) exhibit novel effects on apoptosis of cardiomyocytes. These substances are capable of greatly decreasing apoptosis by a pathway that is not Caspase 3 dependent. Addition of IGF1 to the treatment further prevents apoptosis. Glitazones alone or glitazones plus IGF1 should be administered at the beginning of a myocardial infarction and continued through the recuperation period to reduce morbidity and prevent unfavorable remodeling of the myocardium.
机译:已经证明抗糖尿病的噻唑烷和恶唑烷衍生物(格列酮类)对心肌细胞的凋亡表现出新的作用。这些物质能够通过不依赖Caspase 3的途径大大减少细胞凋亡。在治疗中加入IGF1可以进一步防止细胞凋亡。在心肌梗塞开始时应单独使用格列唑酮或格列酮加IGF1,并在休养期持续服用,以减少发病率并防止心肌重塑。

著录项

  • 公开/公告号AU4005299A

    专利类型

  • 公开/公告日1999-12-06

    原文格式PDF

  • 申请/专利权人 REGENTS OF THE UNIVERSITY OF CALIFORNIA;

    申请/专利号AU19990040052

  • 发明设计人 PING H. WANG;

    申请日1999-05-19

  • 分类号A61K31/425;A61K31/41;A61K31/42;A61K31/44;

  • 国家 AU

  • 入库时间 2022-08-22 01:51:50

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号